Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327 pISSN 1738-1088

Cited by CrossRef (10)

  1. Zack Blumenfeld, Kallol Bera, Eero Castrén, Henry A. Lester. Antidepressants enter cells, organelles, and membranes. Neuropsychopharmacol. 2024;49:246
    https://doi.org/10.1038/s41386-023-01725-x
  2. Sana Yasin, Alice Othmani, Bouibauan Mohamed, Imran Raza, Syed Asad Hussain. Depression detection and subgrouping by using the active and passive EEG paradigms. Multimed Tools Appl 2024
    https://doi.org/10.1007/s11042-024-19184-x
  3. Ruixue Liu, Chunxiao Liu, Dianwei Feng, Tongxin Guo, Ying Wang. Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database. Front. Pharmacol. 2024;15
    https://doi.org/10.3389/fphar.2024.1414703
  4. Vivian W.L. Tsang, Brendan Tao, Shannon Dames, Zach Walsh, Pam Kryskow. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Therapeutic Advances in Psychopharmacology 2023;13:204512532311715
    https://doi.org/10.1177/20451253231171512
  5. John H. Krystal, Alfred P. Kaye, Sarah Jefferson, Matthew J. Girgenti, Samuel T. Wilkinson, Gerard Sanacora, Irina Esterlis. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proc. Natl. Acad. Sci. U.S.A. 2023;120
    https://doi.org/10.1073/pnas.2305772120
  6. Wooyoung Jung, Eunsoo Moon, Hyun Ju Lim, Je Min Park, Byung Dae Lee, Young Min Lee, Heejeong Jeong, Hwagyu Suh, Kyungwon Kim. The Dropout Rates and Associated Factors in Patients with Mood Disorders in Long-term Naturalistic Treatment. Clin Psychopharmacol Neurosci 2024;22:263
    https://doi.org/10.9758/cpn.23.1089
  7. Michael D. Kritzer, Chi-Un Pae, Prakash S. Masand. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opinion on Drug Safety 2022;21:725
    https://doi.org/10.1080/14740338.2022.2069749
  8. M. Fornaro, C.I. Cattaneo, D. De Berardis, F.V. Ressico, G. Martinotti, E. Vieta. Antidepressant discontinuation syndrome: A state-of-the-art clinical review. European Neuropsychopharmacology 2023;66:1
    https://doi.org/10.1016/j.euroneuro.2022.10.005
  9. Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, Eleonora Arsenio, Andrea D’Arpa, Antonio Volpicelli, Mario Luciano, Gaia Sampogna, Andrea Fiorillo. Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Front. Psychiatry 2024;15
    https://doi.org/10.3389/fpsyt.2024.1394787
  10. Carolyn F. Kundert, Robert M. Sobule, Muaid Ithman. Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression. 2024;37:28
    https://doi.org/10.1097/01.JAA.0000000000000036